Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject voluntarily gives informed consent to participate in the study.~2. The subject participated in study RIN-PH-201, remained on study drug, was compliant with RIN-PH-201 study procedures or was enrolled in study RIN-PH-201 at the time that the study was discontinued by the sponsor.~3. Females of reproductive potential must be non-pregnant (as confirmed by a urine pregnancy test at Baseline) and non-lactating, and will:~   * Either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or~  * Use two medically acceptable, highly-effective forms of contraception for the duration of study, and at least 30 days after discontinuing study drug.~4. Males must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.~Exclusion Criteria:~1. The subject is pregnant or lactating.~2. The subject was prematurely discontinued from study RIN-PH-201.~3. The subject developed a concurrent illness or condition during the conduct of RIN-PH-201 which, in the opinion of the Investigator, would represent a risk to overall health if they enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled Treprostinil (Type: EXPERIMENTAL): Open-label access

Based on this trial design, predict the completion outcome and termination type (if applicable).